Researchers identify existing drug's potential for triple negative breast cancer
Researchers identify existing drug’s potential for triple negative breast cancer 28th January 2021 Researchers at The Institute of Cancer Research, London (ICR) have identified an already approved breast cancer drug which could have promise in the treatment of triple negative breast cancer (TNBC). The study, funded by research and care charity Breast Cancer Now, suggests that palbociclib – marketed by Pfizer as Ibrance – could be used to treat around a fifth of people with TNBC. The research discovered a way to identify TNBC tumours that could be more likely to respond to CDK4/6 inhibit...